Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Phase 1

• Conditions: Lymphoma
• Interventions: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

• Registration Number: NCT03086954
• Lead Sponsor: Sinobioway Cell Therapy Co., Ltd.

Brief Summary

This open, single-arm,multicenter 2 phase clinical study will treat the patient who have CD19 positive lymphoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor(CAR)that will bind to tumour cells modified to express the CD19 protein on the cell surface. The study will determine if these modified T cells help the body's immune system eliminate tumour cells .The trial will also study the safety of treatment for CAR-T, how long CAR-T cells stay in the patient's body and the impact on this treatment for survival.

Detailed Description

This is an open, single-arm,multicenter 2 phase clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD19 positive lymphoma. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the following sequential phases: part A (screening, leukapheresis, cell product preparation and cytoreductive chemotherapy) and part B (treatment and follow-up). The follow-up period for each participant is approximately 35 months after the final CAR-T infusion. The total duration of the study are expected to be approximately 3 years. A total of 24 patients may be enrolled over a period of 3 years.

Study Timeline

• Status Verified: 2017-03
• Study First Submitted: 2017-03-13
• Study First Submitted QC: 2017-03-21
• Last Update Submitted: 2017-03-21
• Study First Posted: 2017-03-22
• Last Update Posted: 2017-03-22
• Study Start: 2017-04
• Primary Completion: 2021-03
• Study Completion: 2021-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• 1.Age older than 16 years old,gender and race no limited.
• 2.Pathological diagnosis of CD19 express positive recurrent or refractory B lymphoma, satisfy any of the following a diagnosis of recurrent or refractory lymphoma: (1) According to the standard solution standardization more than four courses of treatment, tumor size < 50% or progression;(2) According to the standard solution treatment of complete remission, after recurrence again with the original plan or the national expert consensus recommended second-line cannot again get to complete remission (3) Relapse after hematopoietic stem cell transplantation.
• 3.Patients into the group needs lesions to be available for testing or evaluating disease.
• 4.ECOG score reaches 0 to 1 points.
• 5.Patients into the group of White Blood Cell counts in peripheral blood acuity≥ 1.0 x10^9 / L.
• 6.Estimated survival times > 90 days.
• 7.Patients have self-knowledge ability, can sign the informed consent form.

Exclusion Criteria

• 1.Pregnant or lactating women.
• 2.Uncontrolled infection.
• 3.HIV infection, hepatitis B or C activity period.
• 4.Patients who need long-term immunosuppressive therapy (Such as allergies, autoimmune diseases, GVHD, etc.)
• 5.Combined activity of the central nervous system malignant tumor invasion.
• 6.Abnormal coagulation function, patients with severe thrombosis.
• 7. Organ failure Heart：class Ⅱ or above. Liver：class Ⅱ or above( Refer to Classification of Wuhan Conference (1983)). Kidney: The second stage of renal insufficiency or above. Lung: class Ⅱdecreased slightly or above. Brain: The central nervous system transfer or have active lesions.
• 8.Patients who have participated in other clinical trials in the past 30 days or or participate in other clinical trials at the same time.
• 9.Investigator believe that the patient is not suitable to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
single arm	The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)	Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times

Primary Outcome Measures

Name	Time	Method
The objective reaction rate of patients with CD19 positive lymphoma after autologous CAR-T cell therapy.	up to 90 days	The objective reaction rate will be determined by the evaluation of CT/PET-CT.Evaluation of the objective reaction rate according to the non-hodgkin's lymphoma curative effect evaluation criteria of international lymphoma group. The objective reaction rate = (complete remission (CR) number + partial remission (PR) number / total number of cases receiving treatment.

Secondary Outcome Measures

Name	Time	Method
3°or above incidence rate of serious adverse reaction related to treatment	3years	According to CTCAE v4.0 to evaluate incidence rate of serious adverse reaction.
Progression free survival time	3years	From patients into the group to the interval between disease progression or death.
Overall survival time	3years	From all patients into the group to the interval between death caused by any reason .
Patients - -based Quality of Life Evaluation	3years	According to the EORTC quality of life of the core scale criteria QLQ-C30(V3.0) to evaluate patients life quality.

Trial Locations

Locations (1)

Jiangsu Cancer hospital; 🇨🇳 Nanjing, Jiangsu, China